Regeneron (REGN) Tops Q2 EPS by 104c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Reports Second Quarter 2017 Financial and Operating Results
August 3, 2017 6:30 AM EDTTARRYTOWN, N.Y., Aug. 3, 2017 /PRNewswire/ -- Â
Second quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 11% to $919 million versus second quarter 2016 Second quarter 2017 EYLEA global net sales(1) increased 11% to $1.46 billion versus second quarter 2016 Raised estimated full year 2017 EYLEA U.S. net sales growth guidance to approximately 10% over 2016 Kevzara® (sarilumab) approved by FDA and European Commission for adults with moderately to severely active rheumatoid arthritisRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2017 and provided a business... More
